Recent Biosimilar Commercialization Developments
LexBlog IP
SEPTEMBER 28, 2023
has announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceuticals Co., According to the press release, the first molecules subject to the agreement are expected to launch as early as 2025. Insulin Biosimilars: Meitheal Pharmaceuticals, Inc. Anti-Tumor Biosimilars: Chime Biologics Ltd.,
Let's personalize your content